{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["6(1)"],"submitter":["Heinhuis KM"],"pubmed_abstract":["<h4>Importance</h4>Multiple immunostimulatory agonist antibodies have been clinically tested in solid tumors to evaluate the role of targeting glucocorticoid-induced tumor necrosis factor (TNF) receptor-related protein in anticancer treatments.<h4>Objective</h4>To evaluate the safety and activity of the fully human glucocorticoid-induced TNF receptor-related protein agonist IgG1 monoclonal antibody BMS-986156 with or without nivolumab in patients with advanced solid tumors.<h4>Design, setting, and participants</h4>This global, open-label, phase 1/2a study of BMS-986156 with or without nivolumab enrolled 292 patients 18 years or older with advanced solid tumors and an Eastern Cooperative Oncology Group performance status of 1 or less. Prior checkpoint inhibitor therapy was allowed. Monother"],"journal":["JAMA oncology"],"pagination":["100-107"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6865300"],"repository":["biostudies-literature"],"pubmed_title":["Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial."],"pmcid":["PMC6865300"],"pubmed_authors":["Gazzah A","Heinhuis KM","Paz-Ares L","Britschgi C","Romano E","Joerger M","Di Nicola M","Meniawy T","Liu Y","Patah P","Delord JP","Moreno V","Curigliano G","Wang R","Carlino M","Rottey S","Schilder RJ","O'Byrne K","Siu LL","Bajaj G"],"additional_accession":[]},"is_claimable":false,"name":"Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial.","description":"<h4>Importance</h4>Multiple immunostimulatory agonist antibodies have been clinically tested in solid tumors to evaluate the role of targeting glucocorticoid-induced tumor necrosis factor (TNF) receptor-related protein in anticancer treatments.<h4>Objective</h4>To evaluate the safety and activity of the fully human glucocorticoid-induced TNF receptor-related protein agonist IgG1 monoclonal antibody BMS-986156 with or without nivolumab in patients with advanced solid tumors.<h4>Design, setting, and participants</h4>This global, open-label, phase 1/2a study of BMS-986156 with or without nivolumab enrolled 292 patients 18 years or older with advanced solid tumors and an Eastern Cooperative Oncology Group performance status of 1 or less. Prior checkpoint inhibitor therapy was allowed. Monother","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Jan","modification":"2026-04-12T23:52:11.266Z","creation":"2021-02-19T10:38:35Z"},"accession":"S-EPMC6865300","cross_references":{"pubmed":["31697308"],"doi":["10.1001/jamaoncol.2019.3848"]}}